Chronopharmacology and mechanism of antitumor effect of erlotinib in Lewis tumor-bearing mice

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Wang, Peipei ^a   An, Fengmei ^b   Zhuang, Xingjun ^b   Liu, Jiao ^a   Zhao, Liyan ^b   Zhang, Bin ^b   Liu, Liang ^a   Lin, Pingping ^a   Li, Mingchun ^a  

^a QINGDAO UNIVERSITY MEDICAL COLLEGE   (China)

^b 401 Hospital of PLA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE 4; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; ANTINEOPLASTIC AGENT; PHOSPHOPROTEIN; QUINAZOLINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BODY WEIGHT; CANCER INHIBITION; CHRONOPHARMACOLOGY; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; FEMALE; GENE EXPRESSION; LIGHT DARK CYCLE; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; QUALITY OF LIFE; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; TUMOR VOLUME; WESTERN BLOTTING; ANIMAL; CELL PROLIFERATION; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; HUMAN; LUNG TUMOR; METABOLISM; PATHOLOGY; TIME; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MICE; PHOSPHOPROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; TIME FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84904382771     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0101720     Document Type: Article

References (31)

1. Hastings MH, Reddy AB, Maywood ES (2003) A clockwork web: circadian timing in brain and periphery, in health and disease. Nat. Rev. Neurosci 4:649-61. (Pubitemid 37280160)
2. Aschoff J (1963) Comparative physiology: Diurnal rhythms. Annu Rev Physiol 25:581-600.
3. Harbour VL, Weigl Y, Robinson B, Amir S (2013) Comprehensive Mapping of Regional Expression of the Clock Protein PERIOD2 in Rat Forebrain across the 24-h Day. Plos One 8: e76391.
4. -/- mutant mice. Genes & Development 17:1366-1379.
5. Xian LJ, Jian S, Cao QY, Ye YL, Liu XH, et al. (2002) Circadian Rhythms of DNA Synthesis in Nasopharyngeal Carcinoma Cells. Chronobiol. Int 19 (1):69-76. (Pubitemid 34310821)
6. Hrushesky WJ (1985) Circadian timing of cancer chemotherapy. Science 228:73-75.
7. Ohdo S (2007) Circadian Rhythms in the CNS and Peripheral Clock Disorders: Chronopharmacological Findings on Antitumor Drugs. J Pharmacol Sci 103, 155-158.
8. Herbst RS, Langer CJ (2002) Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung,and head and neck cancers. Semin Oncol 29: 27-36. (Pubitemid 34226516)
9. Perez-Soler R (2006) Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer. Clin Lung Cancer 8: S7-S14.
10. Paz-ares L, Sanchez JM, Garcia-Velasco A (2006) A prospecitive phase II trial of erlotinib in advanced non-small cell lung cell (NSCLC) patients(p) with mutation in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR). J. Clin Oncol 24: 369-375.
11. Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, et al. (2005) TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non small cell lung cancer. J Clin Oncol 23(25): 5892-5899.
12. Albanell J, Rojo F, Averbuch S,Feyereislova A, Mascaro JM, et al. (2002) Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: Histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 20:110-124. (Pubitemid 34032602)
13. Smolensky MH, Peppas NA (2007) Chronobiology, drug-delivery, and chronotherapeutics. Adv. Drug Deliv. Rev 59:825-27.
14. Kersemaekers AM, Fleuren GJ, Kenter GG, Van Den Broek LJ, Uljee SM, et al. (1999) Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis. Clin Cancer Res 5:577-86. (Pubitemid 29131967)
15. Mendelsohn J (2001) The epidermal growth factor receptor as a target for cancer therapy. Endocr Relat Cancer 8:3-9.
16. Modi S, Seidman AD (2002) An update on epidermal growth factor receptor inhibitors. Curr Oncol Rep 4:47-55.
17. Grunwald V, Hidalgo M (2002) The epidermal growth factor receptor: a new target for anticancer therapy. Curr Probl Cancer 26:109-64. (Pubitemid 35024520)
18. Ritter CA, Arteaga CL (2003) The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors. Semin Oncol 30:3-11. (Pubitemid 36307612)
19. Darzacq X, Jady BE, Verheggen C, Kiss AM, Bertrand E, et al. (2002) Cajal body-specific small nuclear RNAs: a novel class of 2′-O-methylation and pseudouridylation guide RNAs. EMBO J. 21:2746-2756. (Pubitemid 34619390)
20. Wang XS, Diener K, Jannuzzi D, Trollinger D, Tan TH, et al. (1996) Molecular cloning and characterization of a novel protein kinase with a catalytic domain homologous to mi togen-ctivated protein kinase kinase kinase. J Biol Chem 271: 31607-31611. (Pubitemid 26408622)
21. Xu F, Tian Y, Huang Y, Zhang YY, Guo ZZ, et a1 (2011) EGFR inhibitous sensitize non-small cell lung cancer cell to TRAIL-induced apoptosis. Chinese Journal of Cancer 30: 701-711.
22. Liu W, Ren H, Ren J, Yin T, Hu B, et al. (2013) The Role of EGFR/PI3K/Akt/cyclinD1 Signaling Pathway in Acquired Middle Ear Cholesteatoma. Mediators of Inflammation Available: http://dx.doi.org/10.1155/2013/651207. Accessed 2013 September 24.
23. Eriguchi M, Levi F, Hisa T, Yanaqie H, Nonaka Y, et a1 (2003) Chronotherapy for cancer. Biomed Pharmacother (Suppl 1):92.
24. Ohdo S, Inoue K, Yukawa E, Hiquchi S, Nakano S, et al. (1997) Chronotoxicity of methotrexate in mice and its relation to circadian rhythm of DNA synthesis and pharmacokinetics. Jpn. J. Pharmacol. 75: 283-290. (Pubitemid 28000173)
25. Filipski E, Amat S, Lemaigre G, Vincenti M, Breillout F, et al. (1999) Relationship between circadian rhythm of vinorelbion toxicity and efficacy in P388-bearing mice. J Pharmacol Exp Ther 289(1):231-235. (Pubitemid 29156034)
26. Patel DM, Jani RH, Patel CN (2011) Design and evaluation of colon targeted modified puldincap delivery of 5-fluorouracil according to circadian rhythm. Int J Pharm Investig 1(3): 172-181.
27. Bjamason GA, Jordan R (2002) Rhythms in Human gastrointestinal Mucosa and Skin. Chronobiol Int 19(1):129-140.
28. Smaaland R, Sothem RB, Laerum OD, Abrahamsen JF (2002) Laerum Rhythms in human bone marrow and blood cells. Chronobiol Int 19(1):101-127. (Pubitemid 34326438)
29. Abolmaali K, Balakrishnan A, Stearns AT, Rounds J, Rhoads DB, et a1 (2009) Circadian variation in intestinal dihydropyrimidine dehydrogenase(DPD) expression: A potential mechanism for benefits of 5-FU chronochemotherapy. Surgery 146(2):269-273.
30. Wei Q, Sheng L, Shui Y, Hu Q, Nordqren H, et al. (2008) EGFR, HER2, and HER3 Exp ression in Laryngeal Primary Tumors and Corresponding Metastases. Ann Surg Oncol 15 (4): 1193-1201.
31. Morshed K, Skomra D, Korobowicz E, Szymariski M, Polz-Dacewicz M, et al. (2007) An immunohistochemical study of cyclinD1 protein exp ression in laryngeal squamous cell carcinoma. Acta Otolaryngol 127 (7):760-769. (Pubitemid 46934128)